Taken together, our findings indicated that SRPK1 overexpression increased tEGFR expression and shortened the time interval for disease progression in advanced NSCLC patients receiving TKI therapy, resulting in a poor prognosis. Here, SRPK1 is linked to non-small cell lung carcinoma.